Abstract 17P
Background
Early CD8+ T cell responses to PD-1 blockade are well-characterised. However, an understanding of the long-term clonal and transcriptomic signatures of complete response (CR) to Immune Checkpoint Blockade (ICB) is currently lacking. We aimed to identify and describe CD8+ T cell clonal and transcriptomic changes post complete response to PD-1 blockade in metastatic melanoma (MM).
Methods
We performed single-cell RNA sequencing (scRNAseq) of both the T cell receptor (TCR) and transcriptomes of PBMCs and sorted peripheral CD8+ T cells in patients with MM with a complete response to PD-1 blockade (n=10), patients with progressive disease (PD, n=6) and healthy donors (HD, n=2). Blood was sampled at multiple time points, including a median of 3.2 years following cessation of PD-1 blockade for CR.
Results
Following a CR and cessation of ICB, there is increased abundance of a subtype of CD8+ T cell characterised by high expression of NK-associated genes, termed a killer-like subset. Using the top 25 genes upregulated by this subset to generate a ‘Killer Score’, we show that patients with CR to anti-PD-1 demonstrate a broad increase in killer gene expression over time absent in those with PD and HDs. By tracking key clones through TCR usage, we identify those which are stable/expanding from pre-treatment to post treatment, occupy >0.5% of the repertoire and are persistent post-cessation of ICB, terming these large expanding persistent clones. These clones have a predominantly cytotoxic, effector, gene expression profile and display surface markers consistent with a recently-described ‘Long-lived Effector Cell’ subtype.
Conclusions
CR to PD-1 blockade is associated with persistence of highly-cytotoxic effector CD8+ T cells that circulate years after cessation of treatment. Whilst similar subsets have been implicated with chronic viral infection, these observations are novel in the cancer setting and have important implications for mechanisms of durable disease control.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The Wellcome Trust, Cancer Research UK, National Institute for Health Research.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
46P - Effect of coadministration of antioxidant chlorophyllin with docetaxel on invasion and metastasis in triple-negative breast cancer in vivo/in vitro
Presenter: Ayse Burus
Session: Poster session 09
47P - An ozone delivery system by cisplatin prodrug self-assembling micelles combining microwave to sensitizing immune checkpoint inhibitor in triple-negative breast cancer
Presenter: Dan Zheng
Session: Poster session 09
48P - Non-steroid anti-inflammatory treatment enhances the efficacy of modulated electro hyperthermia on triple-negative breast cancer and melanoma cancer models in vivo
Presenter: Nino Giunashvili
Session: Poster session 09
49P - Circulating miRNA signatures to predict recurrence in patients with pathological complete response of triple-negative breast cancer
Presenter: Ana Julia de Freitas
Session: Poster session 09
50P - Application and mechanism of tarloxotinib in HER2-positive breast cancer
Presenter: Xinyi Shao
Session: Poster session 09
51P - Nanoengineered sonosensitive platelets for synergistically augmented sonodynamic breast tumour therapy by glutamine deprivation and cascading thrombosis
Presenter: Liqiang Zhou
Session: Poster session 09
53P - Treatment of cancer cells based on circulating tumor cell’s expression profile using off-label drugs
Presenter: Panagiotis Apostolou
Session: Poster session 09
54P - Enhanced oxidative phosphorylation of metastasis-initiating cells facilitates esophageal tumor cell seeding in lymph nodes
Presenter: Shanshan Li
Session: Poster session 09
55P - Transcriptional profiles of engineered T cells stimulated with different receptor structures and co-stimulatory domains
Presenter: Ungue Shin
Session: Poster session 09
56P - SLC34A2-ROS1 L2026M+G2032R confers resistance to ROS1 tyrosine kinase inhibitors in Ba/F3 cells through a reduced ATP binding pocket volume
Presenter: Christa Dijkhuizen
Session: Poster session 09